Applied Genetic Technologies Corp

NASDAQ:AGTC  
3.88
+0.21 (+5.72%)
Earnings Announcements

AGTC Provides Trial Reports Financial Results For The Fourth Quarter And Year Ended June 30

Published: 09/09/2020 13:52 GMT
Applied Genetic Technologies Corp (AGTC) - Agtc Provides Trial Design Update for Its Phase 2/3 Xlrp Clinical Trial, New Data on Xlrp Higher Dose Group and Financial Results for the Fourth Quarter and Year Ended June 30, 2020.
Applied Genetic Technologies Corp - Planned Phase 2/3 Trial Expected to Include Approximately 60 Patients.
Applied Genetic Technologies Corp - Data From Group 5 Supports Use of Higher Dose Level in Phase 2/3 Trial.
Applied Genetic Technologies Corp - on Track to Provide Multiple Data Readouts for Xlrp and Achm Clinical Programs in 4q.
Applied Genetic Technologies Corp - As of June 30, 2020, Company's Cash, Cash Equivalents and Investments Totaled $80.5 Million.
Applied Genetic Technologies Corp - No Revenue for Q4 of 2020.
Applied Genetic Technologies Corp - Qtrly Loss per Share $0.56.
Applied Genetic Technologies Corp - Believes Funds Will Be Sufficient for Ongoing Clinical Programs, to Fund Other Programs Into Q4 2021.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.41

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.42

More details on our Analysts Page.